Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. - Test2 - elhamkhani - TriplyDB

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

http://www.wikidata.org/entity/Q30224854

about

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques The potential of plants as a system for the development and production of human biologics Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents Gene delivery into plant cells for recombinant protein production.Cell-targeting antibodies in immunity to Ebola Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Generation and analysis of novel plant-derived antibody-based therapeutic molecules against West Nile virus.Designed IgM from glycoengineering.Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes.Vaccinating captive chimpanzees to save wild chimpanzees.A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.Plant glyco-biotechnology on the way to synthetic biology Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp An update on the use of antibodies against the filoviruses.Structures of protective antibodies reveal sites of vulnerability on Ebola virus.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Chemical and Structural Aspects of Ebola Virus Entry Inhibitors.Glycome characterization of immunoglobulin G from buffalo (Bubalus bubalis) colostrum.Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.Leishmania tarentolae: an alternative approach to the production of monoclonal antibodies to treat emerging viral infections.Isotype-specific glycosylation analysis of mouse IgG by LC-MS.Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination.Microscale purification of antigen-specific antibodies.Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants.Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.Potential vaccines and post-exposure treatments for filovirus infections.Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides Monoclonal antibody therapy for Junin virus infection.Antibody therapeutics for Ebola virus disease.Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic.Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus.Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.Glycoengineering of plants yields glycoproteins with polysialylation and other defined N-glycoforms.Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.Enrichment strategies in glycomics-based lung cancer biomarker development.Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.Glyco-engineering in plants to produce human-like N-glycan structures.

P2860

Q24612811-5368433B-1C12-4CE4-95AF-39286E861430 Q26747611-3B7899A8-322E-4223-A33F-78302DED1DD4 Q26783107-40BBD2EF-FD76-434C-9D99-A0119211F69E Q27691364-A80EB8CA-73B1-491F-951A-CF248D312370 Q28068972-A37A506E-11C7-4E71-BDA0-6E9206A0C918 Q30251949-F2E8CFBD-59AD-4171-AD4E-330C237FA5CB Q30252022-04CCF275-FA0F-400B-8C61-D98C19276B1A Q31154829-098BC23B-70BB-40E3-BA7F-89B23E445D9F Q33674739-559DD017-BD01-4BEB-9E8F-CED84933DCDA Q33757315-33622E24-4D59-4710-B294-B7FAC07C0137 Q33790197-5E803071-F712-4667-8209-E79AFDFFC2EB Q34029668-C49AAE3C-C012-402B-A29A-E264E8A1786E Q34304795-DE437728-F8C0-40AF-A778-F95BBA498C36 Q34426585-2A32E951-F4D5-4EC0-8E6B-2D1D43A9C02E Q34657170-6AE9D6EA-3D05-45F2-98D7-E45D8937D1B3 Q34661120-E6F91B95-A56E-4780-B075-E59FF25B806C Q34869927-44263AD2-3B24-4322-BC04-B375BEE5497C Q35589926-E4128F4D-0648-4604-85C8-72490F0C413F Q35736606-9DD97D83-68F2-475D-BD54-FA336D067841 Q35793699-71C7B07B-6103-4228-A398-9F2EF6B7B416 Q35863259-0E325C0B-FC60-4FB8-B753-2D84A239DF81 Q35951417-E3CBC759-7391-45D7-98F7-EDD401864E5A Q35959717-40369A73-133B-4FA8-B622-D6D0C2CA9977 Q36157114-8D980256-36DC-4F72-9E05-74AF2CAF6023 Q36179265-1B93762D-85C5-4E0C-86D9-546CF778C297 Q36208191-55C5AC44-E918-4423-B05C-B7808899059B Q36404178-F9AFF095-2F73-4880-A89A-A486FE5D6C01 Q36432717-9A900BCC-407D-4290-A773-C623246476A3 Q36785795-4E922D31-A8B3-4E4F-A99C-BD09CB3BC0EB Q36831453-3D824E06-7459-4860-98C1-D60E1234D972 Q36994087-AD1F0392-C71F-4A9A-8B64-E2E3F1DD8709 Q37134982-F739C1B4-6393-43D5-91F9-C53BAB537C20 Q37159302-DB5C263C-C02D-44B0-9A5E-596A0B6A52BF Q37184296-D1256B86-580E-4D34-8FC3-7C601FF4AFAE Q37213813-EC837705-618E-4E85-8081-EEDDA8D4CD39 Q37213985-956C15DA-6AE8-46A1-B76F-C1986EE64DD7 Q37446239-6C6A947F-044F-4F21-972A-2768B3C7629C Q37484236-0A08CB1B-FEB1-4648-BD86-631F55255E60 Q37725351-05C0B75B-3611-4C32-AE06-AB239CA0495D Q38034471-D374EC75-893B-4DF7-944D-BB43FBFC4400

P2860

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

http://www.wikidata.org/entity/Q30224854

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Enhanced potency of a fucose-f ...... Ebola virus immunoprotectant.

@ast

Enhanced potency of a fucose-f ...... Ebola virus immunoprotectant.

@en

type

label

Enhanced potency of a fucose-f ...... Ebola virus immunoprotectant.

@ast

Enhanced potency of a fucose-f ...... Ebola virus immunoprotectant.

@en

prefLabel

Enhanced potency of a fucose-f ...... Ebola virus immunoprotectant.

@ast

Enhanced potency of a fucose-f ...... Ebola virus immunoprotectant.

@en

P1433

Q30224854-CCE37D44-8D27-416A-BDBE-C2108D677886

P1476

Q30224854-34277F0F-B887-4F87-8169-E6264FE135F7

P2093

Q30224854-2B35B4E5-6403-4B7C-8D21-E6C8A18775E6

Q30224854-485EC5A5-BB7D-4A2A-B857-92A7E227E280

Q30224854-4911610C-A62C-4F0F-9B0C-97A4743B7551

Q30224854-5E9739A9-04CD-4720-976D-F719A0F56C96

Q30224854-658EC442-C75F-45CE-86B7-18FE7EA2CB4E

Q30224854-9765CB7A-DD48-4D2F-90F3-4E52920CB3CE

Q30224854-9A17302C-9928-40CB-954B-0635A9F4AAE7

Q30224854-CF3CDD83-BEB8-488C-A7F8-1F0D165FFA89

Q30224854-E61B12F9-CF18-4BBE-AAC7-0B6BE5EB95A7

P2860

Q30224854-0416663B-4D8C-4630-A509-764DB0229087

Q30224854-0D5A136D-86D6-44F6-8B54-BFECEB945644

Q30224854-162EA5B2-9487-4C01-8DA2-87AA4979EA0A

Q30224854-1721E907-971E-408C-8ACE-635EF56010D1

Q30224854-1AEF4BF6-3F03-43FF-B124-6F2C13171FCF

Q30224854-1BA29393-27DA-4B9D-9ECE-37CB0C520835

Q30224854-1CC28EE5-33BE-4EEC-BF80-59BE5420EB5B

Q30224854-1E732061-3878-4751-AA2D-80A1E110DC19

Q30224854-2CD47BC6-32EC-4CC0-8912-9CE141A2876F

Q30224854-4243BBA4-E82D-49A2-A61E-BBE920200C94

P304

Q30224854-80308CD5-DAD8-48AD-9C81-C08B994D8842

P31

Q30224854-04750C8D-A235-4780-9E95-B82FE8A88001

P356

Q30224854-09E663D4-7D7C-40D0-909B-54A6C835F7CE

P407

Q30224854-E689601F-71B8-4A7F-ACDF-798A8CE41B61

P433

Q30224854-5792C8A0-F895-48B1-B277-0334582D9C34

P478

Q30224854-6144F6B4-6009-4DB2-A0FC-2FD273B292F5

P50

Q30224854-17DD3505-EB7D-48C9-8CC9-99B222703EFD

Q30224854-CE8AB5CB-C70F-43FF-9B9E-7F8A3741B9D2

P577

Q30224854-618939DC-C7FA-4360-8E54-F5588627E5EC

P5875

Q30224854-085A05A1-E439-41A8-99C8-8BDC072F2B0A

P698

Q30224854-11D9E2EA-3149-410E-817F-D65FDA3E7A51

P921

Q30224854-0DE6005E-5F5C-4B2C-8D0E-2CA29C72D368

Q30224854-FC32ADB7-8341-4F9E-B331-0D1C445BE31F

P932

Q30224854-0BF3D5D7-5244-4D7E-AFCC-B25D89A84C81

P356

PNAS.1108360108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Enhanced potency of a fucose-f ...... Ebola virus immunoprotectant.

@en

P2093

Andrew Hiatt

http://www.w3.org/2001/XMLSchema#string

Corinne Scully

http://www.w3.org/2001/XMLSchema#string

Do Kim

http://www.w3.org/2001/XMLSchema#string

James Pettitt

http://www.w3.org/2001/XMLSchema#string

Kevin J Whaley

http://www.w3.org/2001/XMLSchema#string

Larry Zeitlin

http://www.w3.org/2001/XMLSchema#string

Long Ngo

http://www.w3.org/2001/XMLSchema#string

Michael Pauly

http://www.w3.org/2001/XMLSchema#string

Natasha Bohorova

http://www.w3.org/2001/XMLSchema#string

P2860

Complex of a Protective Antibody with Its Ebola Virus GP Peptide Epitope: Unusual Features of a Vλx Light Chain

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides

Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants.

In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium.

Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors.

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.

Engineered antibodies with increased activity to recruit complement.

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity

P304

20690-20694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1108360108

http://www.w3.org/2001/XMLSchema#string

P407

P433

51

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Herta Steinkellner

P577

2011-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51854847

http://www.w3.org/2001/XMLSchema#string

P698

22143789

http://www.w3.org/2001/XMLSchema#string

P921

P932

3251097

http://www.w3.org/2001/XMLSchema#string